Psilocybin-facilitated Treatment for Chronic Pain
Randomised, double-blind, parallel-group study (n=30) testing a single oral dose of psilocybin (0.36 mg/kg) versus active placebo (dextromethorphan 2.6 mg/kg) for fibromyalgia.
Details
Randomised, double-blind, parallel-group trial evaluating psilocybin-assisted treatment for fibromyalgia with 30 female participants, comparing 0.36 mg/kg psilocybin to 2.6 mg/kg dextromethorphan (active placebo).
Participants receive preparatory therapy (minimum two 2-hour sessions), a single 8‑hour supervised dosing session with physiological monitoring, and an integration session the following day; outcomes include pain, fatigue, functioning and quality of life.
Additional measures assess potential mediators such as expectations, pain characteristics, personality and cognitive/emotional factors; participants complete follow-up at ~6 weeks.